[Passive immunotherapy in Sars-Cov2 infections]

Ioanna Christodoulou1, Jacques H M Cohen2

  • 1Institut Lavoisier de Versailles, UMR CNRS 8180, Université Paris-Saclay, Université de Versailles St-Quentin-en-Yvelines 78035 Versailles cedex, France.

This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus.